Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1397053rdf:typepubmed:Citationlld:pubmed
pubmed-article:1397053lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:1397053lifeskim:mentionsumls-concept:C0027819lld:lifeskim
pubmed-article:1397053lifeskim:mentionsumls-concept:C0017638lld:lifeskim
pubmed-article:1397053lifeskim:mentionsumls-concept:C2936526lld:lifeskim
pubmed-article:1397053lifeskim:mentionsumls-concept:C0065818lld:lifeskim
pubmed-article:1397053lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:1397053lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:1397053lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:1397053lifeskim:mentionsumls-concept:C0740030lld:lifeskim
pubmed-article:1397053lifeskim:mentionsumls-concept:C0173168lld:lifeskim
pubmed-article:1397053pubmed:issue1lld:pubmed
pubmed-article:1397053pubmed:dateCreated1992-11-6lld:pubmed
pubmed-article:1397053pubmed:abstractTextIn radioligand binding experiments, MDL 73147EF and MDL 74156 inhibited the binding of [3H]GR65630 to 5-hydroxy-tryptamine3 (5-HT3) binding sites on membranes prepared from NG108-15 neuroblastoma x glioma cells. The calculated dissociation constants (KI) were 20.03 +/- 6.58 and 0.44 +/- 0.18 nM, respectively (means +/- S.E.M., n = 6 and 9, respectively). Application of 5-HT (10-50 microM) to voltage-clamped NG108-15 cells elicited a rapidly desensitizing inward membrane current, characteristic for the activation of 5-HT3 receptors. The 5-HT-induced membrane current was suppressed in a reversible, concentration-dependent manner by MDL 73147EF and MDL 74156EF. The concentrations required to block half the 5-HT response (IC50) were 3.8 and 0.1 nM, respectively. It is concluded that both compounds are potent and reversible antagonists at 5-HT3 receptors in this neuroblastoma cell line.lld:pubmed
pubmed-article:1397053pubmed:languageenglld:pubmed
pubmed-article:1397053pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1397053pubmed:citationSubsetIMlld:pubmed
pubmed-article:1397053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1397053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1397053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1397053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1397053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1397053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1397053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1397053pubmed:statusMEDLINElld:pubmed
pubmed-article:1397053pubmed:monthAuglld:pubmed
pubmed-article:1397053pubmed:issn0014-2999lld:pubmed
pubmed-article:1397053pubmed:authorpubmed-author:GalvanMMlld:pubmed
pubmed-article:1397053pubmed:authorpubmed-author:SiegelB WBWlld:pubmed
pubmed-article:1397053pubmed:authorpubmed-author:DudleyM WMWlld:pubmed
pubmed-article:1397053pubmed:authorpubmed-author:BaronB MBMlld:pubmed
pubmed-article:1397053pubmed:authorpubmed-author:SloneA LALlld:pubmed
pubmed-article:1397053pubmed:authorpubmed-author:BoeijingaP...lld:pubmed
pubmed-article:1397053pubmed:issnTypePrintlld:pubmed
pubmed-article:1397053pubmed:day14lld:pubmed
pubmed-article:1397053pubmed:volume219lld:pubmed
pubmed-article:1397053pubmed:ownerNLMlld:pubmed
pubmed-article:1397053pubmed:authorsCompleteYlld:pubmed
pubmed-article:1397053pubmed:pagination9-13lld:pubmed
pubmed-article:1397053pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:1397053pubmed:meshHeadingpubmed-meshheading:1397053-...lld:pubmed
pubmed-article:1397053pubmed:meshHeadingpubmed-meshheading:1397053-...lld:pubmed
pubmed-article:1397053pubmed:meshHeadingpubmed-meshheading:1397053-...lld:pubmed
pubmed-article:1397053pubmed:meshHeadingpubmed-meshheading:1397053-...lld:pubmed
pubmed-article:1397053pubmed:meshHeadingpubmed-meshheading:1397053-...lld:pubmed
pubmed-article:1397053pubmed:meshHeadingpubmed-meshheading:1397053-...lld:pubmed
pubmed-article:1397053pubmed:meshHeadingpubmed-meshheading:1397053-...lld:pubmed
pubmed-article:1397053pubmed:meshHeadingpubmed-meshheading:1397053-...lld:pubmed
pubmed-article:1397053pubmed:meshHeadingpubmed-meshheading:1397053-...lld:pubmed
pubmed-article:1397053pubmed:meshHeadingpubmed-meshheading:1397053-...lld:pubmed
pubmed-article:1397053pubmed:meshHeadingpubmed-meshheading:1397053-...lld:pubmed
pubmed-article:1397053pubmed:meshHeadingpubmed-meshheading:1397053-...lld:pubmed
pubmed-article:1397053pubmed:meshHeadingpubmed-meshheading:1397053-...lld:pubmed
pubmed-article:1397053pubmed:year1992lld:pubmed
pubmed-article:1397053pubmed:articleTitleCharacterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells.lld:pubmed
pubmed-article:1397053pubmed:affiliationMarion Merrell Dow Research Institute, Strasbourg, France.lld:pubmed
pubmed-article:1397053pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1397053lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1397053lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1397053lld:pubmed